Protagonist Therapeutics Stock Number Of Shares Shorted
| PTGX Stock | USD 29.61 0.29 0.99% |
Protagonist Therapeutics fundamentals help investors to digest information that contributes to Protagonist Therapeutics' financial success or failures. It also enables traders to predict the movement of Protagonist Stock. The fundamental analysis module provides a way to measure Protagonist Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Protagonist Therapeutics stock.
Protagonist |
Protagonist Therapeutics Company Number Of Shares Shorted Analysis
Protagonist Therapeutics' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Protagonist Therapeutics Number Of Shares Shorted | 3.73 M |
Most of Protagonist Therapeutics' fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Protagonist Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Protagonist Therapeutics has 3.73 M of outstending shares currently sold short by investors. This is 16.73% higher than that of the Biotechnology sector and 26.74% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 20.63% higher than that of the company.
Protagonist Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Protagonist Therapeutics' direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Protagonist Therapeutics could also be used in its relative valuation, which is a method of valuing Protagonist Therapeutics by comparing valuation metrics of similar companies.Protagonist Therapeutics is currently under evaluation in number of shares shorted category among related companies.
Protagonist Fundamentals
| Return On Equity | 0.42 | ||||
| Return On Asset | 0.21 | ||||
| Profit Margin | 0.51 % | ||||
| Operating Margin | 0.81 % | ||||
| Current Valuation | 1.33 B | ||||
| Shares Outstanding | 58.65 M | ||||
| Shares Owned By Insiders | 1.24 % | ||||
| Shares Owned By Institutions | 98.76 % | ||||
| Number Of Shares Shorted | 3.73 M | ||||
| Price To Earning | (4.81) X | ||||
| Price To Book | 4.68 X | ||||
| Price To Sales | 26.26 X | ||||
| Revenue | 60 M | ||||
| Gross Profit | 26.58 M | ||||
| EBITDA | (90.34 M) | ||||
| Net Income | (78.95 M) | ||||
| Cash And Equivalents | 291.89 M | ||||
| Cash Per Share | 5.95 X | ||||
| Total Debt | 1.14 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 7.59 X | ||||
| Book Value Per Share | 9.56 X | ||||
| Cash Flow From Operations | (70.24 M) | ||||
| Short Ratio | 6.86 X | ||||
| Earnings Per Share | 2.54 X | ||||
| Target Price | 44.8 | ||||
| Number Of Employees | 124 | ||||
| Beta | 2.08 | ||||
| Market Capitalization | 1.66 B | ||||
| Total Asset | 357.95 M | ||||
| Retained Earnings | (615.71 M) | ||||
| Working Capital | 334.3 M | ||||
| Current Asset | 83.24 M | ||||
| Current Liabilities | 6.43 M | ||||
| Net Asset | 357.95 M |
About Protagonist Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Protagonist Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protagonist Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protagonist Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Protagonist Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Protagonist Therapeutics' short interest history, or implied volatility extrapolated from Protagonist Therapeutics options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Protagonist Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Protagonist Therapeutics Piotroski F Score and Protagonist Therapeutics Altman Z Score analysis. For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.Note that the Protagonist Therapeutics information on this page should be used as a complementary analysis to other Protagonist Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for Protagonist Stock analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |
Is Protagonist Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagonist Therapeutics. If investors know Protagonist will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protagonist Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Protagonist Therapeutics is measured differently than its book value, which is the value of Protagonist that is recorded on the company's balance sheet. Investors also form their own opinion of Protagonist Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protagonist Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protagonist Therapeutics' market value can be influenced by many factors that don't directly affect Protagonist Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protagonist Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protagonist Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protagonist Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.